Trials / Terminated
TerminatedNCT03240523
A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
A Randomized, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 766 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to describe the efficacy of vilaprisan in subjects with uterine fibroids compared to ulipristal. The secondary objective of this study is to evaluate the efficacy and safety of different treatment regimens of vilaprisan in subjects with uterine fibroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vilaprisan (BAY1002670) | Orally, 2 mg, once daily |
Timeline
- Start date
- 2017-07-31
- Primary completion
- 2020-06-28
- Completion
- 2021-10-25
- First posted
- 2017-08-07
- Last updated
- 2024-10-18
Locations
139 sites across 23 countries: Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Germany, Hungary, Ireland, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, Slovakia, South Korea, Spain, Sweden, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT03240523. Inclusion in this directory is not an endorsement.